Qiagen-backed diagnostic technology developer Xagenic has raised $25.5m in a second closing of its series B round.

Canada-based molecular diagnostics company Xagenic closed the second tranche of a $25.5m series B round featuring molecular biology specialist Qiagen on Monday.

Xagenic received the additional funding from BDC Capital, a subsidiary of the Business Development Bank of Canada. It raised $20m in 2013 in a first tranche led by Domain Associates and featuring Qiagen, venture capital investment partnership CTI Life Sciences Fund and state-backed investment fund Ontario Emerging Technologies Fund.

Xagenic, a spinout from the University of Toronto, is…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?